News specifically tailored to medical oncologists
A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage…
The KEYNOTE-062 phase III randomised clinical trial achieved its primary endpoint, showing that for patients…
The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy…
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and…
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…
A study has shown that more than half of physicians – primary care doctors and…
A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells,…
DEAR MAYO CLINIC: My brother was diagnosed with stage 0 squamous cell carcinoma in situ…
A new modeling study estimates the number, proportion, and type of specific cancers associated with…
At a time when a growing number of men with prostate cancer considered “low risk”…